Anmelden Kostenlos registrieren

Cue Biopharma Inc Bargeld je Aktie

Was ist das Bargeld je Aktie von Cue Biopharma Inc?

Bargeld je Aktie von Cue Biopharma Inc ist 0.24

Was ist die Definition von Bargeld je Aktie?

Barmittel pro Aktie ist der Kassenbestand eines Unternehmens, geteilt durch die ausstehenden Aktien des Unternehmens.

Cash per share, sometimes called the cash share ratio, is the total cash per share. Cash on hand is reported on the balance sheet. Cash per share is calculated by dividing cash on hand by the total number of shares. Cash per share is the percentage of a firm's share price that is immediately accessible for spending. Cash per share consists of cash and short-term investments. It is money that a firm has on hand and does not come from borrowing or financing activities.

When a firm has a high cash per share, significant percentage of its assets is in a very liquid form. This can indicate economic uncertainty and unwillingness to invest given the current economic climate. High levels of cash per share can indicate that a firm is performing well and is able to reinvest in itself but high cash per share does not always indicate overall financial strength.

Bargeld je Aktie von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu Cue Biopharma Inc

Was macht Cue Biopharma Inc?

cue biopharma is an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. we design biologics to engage and modulate the activity of disease-associated t cells in the patient’s body, offering significant therapeutic advantages while potentially minimizing or eliminating unwanted side effects. we believe our biologics allow us to target antigen-specific t cell populations in a variety of indications using a simple peptide exchange within previously-validated drug frameworks developed from the cue biologics platform. this flexibility could truncate the drug selection and development process, moving effective therapeutics from discovery to clinical validation more rapidly and cost efficiently than current industry standard timelines and costs. headquartered in kendall square, cambridge, ma, we are led by an experienced management team and sci

Unternehmen mit bargeld je aktie ähnlich Cue Biopharma Inc